February 2016 Issue of The Translational Scientist

Want a lightning-fast tour of the latest issue? Take a look at our new video sneak preview.

The true mission of translational science is to take new medicines and diagnostics from bench to bedside – and beyond

Could exosome encapsulation be the secret to delivering higher potency in chemotherapy?

Intercepting communication between cancer cells and endothelium uncovers clues to metastasis mechanisms

A protein critical for synaptic plasticity in baby mice could hold clues to the origins of autism

Revolutionary cancer immunotherapies appear to alleviate Alzheimer’s symptoms in mice

A new method could dramatically speed up analysis of nucleic acid thermal behavior

Researchers dive through genetic “junk” to discover a small protein with lots of heart

On each side of the brain stem, a florescent green marker illuminates the two networks of 200 neurons that control the sighing reflex

It’s time to recognize that there is a world beyond genes and proteins. Glycobiology should take its rightful place at the center of biomedical research.

Raising awareness of the hidden beneficiaries of medical innovation could help boost funding for drug development.

Making grant application processes tougher can have an unexpected and dramatic effect on the demographics of applicants. Let’s not force young investigators to fall at the first hurdle.

The vast majority of experimental cancer drugs fail during the later stages of clinical development

The human immunodeficiency virus has evaded the best efforts of vaccine developers for over three decades.

Pancreatic cancer is tough to understand, diagnose and treat. Undeterred researchers are on a quest to crack the case.

The epithelial-to-mesenchymal transition in pancreatic cancer may play a role in its resistance to treatment – and inhibiting it may improve treatment efficacy

A new immunotherapy approach shows that engineered T cells are able to penetrate into pancreatic tumors and directly attack the cancer

When genetics yielded unsatisfactory answers about pancreatic cancer’s persistent survival, researchers looked beyond the genome – and found telling epigenetic changes

It’s often difficult to target pancreatic cancer cells while sparing healthy tissue – but a new therapy concept not only makes this possible, but also enhances the potential effectiveness of adjuvant treatments

A decade after Shinya Yamanaka brought us induced pluripotent stem cells, our ability to generate an endless supply of human heart cells is being put to good use in research and development.

Like many drugs today, pembrolizumab (Keytruda) was the result of a group effort. Here, we catch up with two scientists who shaped the destiny of the biotherapeutic at very different stages in its development.

In today’s highly competitive academic world, are we losing sight of the real goal of biomedical research in our rush to secure funding and embrace the latest technologies?

Sitting Down With… Julian Solway MD, Walter L. Palmer Distinguished Service Professor - Medicine and Pediatrics, Director - Institute for Translational Medicine, Dean for Translational Medicine, University of Chicago, USA.